• Explore /
  • Poster
  • / Nab-paclitaxel plus S-1 as first line treatment for advanced or metastatic biliary tract adenocarcinoma: A phase 2 study.

Nab-paclitaxel plus S-1 as first line treatment for advanced or metastatic biliary tract adenocarcinoma: A phase 2 study.

Abstract Poster

Authors

null

Yongkun Sun

Department of Medical Oncology, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

Yongkun Sun , Ai-Ping Zhou , Wen Zhang , Lin Yang , Chengxu Cui , Zhichao Jiang

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal (Noncolorectal) Cancer

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Hepatobiliary Cancer

Clinical Trial Registration Number

NCT03830606

Citation

J Clin Oncol 37, 2019 (suppl; abstr 4089)

DOI

10.1200/JCO.2019.37.15_suppl.4089

Abstract #

4089

Poster Bd #

194

Abstract Disclosures

Similar Posters

First Author: Ning Li

First Author: Hope Elizabeth Uronis

First Author: Anuj Kishor Patel

First Author: John Ebben